Congrats on taking some gains during that run-up.
Post# of 30028
Posted On: 03/10/2015 11:59:28 PM
Re: Deputy_123 #17890
Congrats on taking some gains during that run-up. I didn't take advantage of that, and I'm okay with that decision. Holding for the long-term payout here.
My conviction in where this company is headed caused me to lock in a $80K tax bill back in October on a large Roth conversion done in 2013 at a 0.036 share price. No undoing that now, and I'm paying that down every time I get paid. It's one reason I returned to work after a 2 year break, to pay that from wages instead of with shares. But if we do uplist to Nasdaq, I will sell enough from my taxable account to wipe out the balance.
I don't believe LymPro is a dud. I think it will be a fine product but will take time to gain traction in the research market. I think Gerald saw an opportunity to corner the AD diagnostic blood test market and took the actions he did to add to the benefit LymPro offers, not because it didn't pan out. I can see that once we bring the full spectrum of blood analysis assets to market, not only will new AD drugs be using multiple tests to screen patients, but many drugs previously failed will be retested under this broad blood-based test series. I believe it quite possible that AD may already have an effective treatment that previously failed due to ineffective screening methods.
I've taken a lot greater risk than most investors in this company. I'm not blind to the risk we continue to face. But one thing I won't do is trash the company because I am unhappy with my investment results to date. I'm not dissatisfied, but I also have an average price of 0.043. I know a lot of folks here are much higher than that, so that affects their frustration level.
If I ever change my outlook on the company's future, I'll quietly sell my shares and move on. I'll make a single post announcing my actions after it's done, and I'll wish everyone the best, but I won't post after I've exited the investment. I'm certainly not going to trash the company publicly while I'm trying to reduce or eliminate my holdings. Only a moron would do that, but that's just my opinion.
My conviction in where this company is headed caused me to lock in a $80K tax bill back in October on a large Roth conversion done in 2013 at a 0.036 share price. No undoing that now, and I'm paying that down every time I get paid. It's one reason I returned to work after a 2 year break, to pay that from wages instead of with shares. But if we do uplist to Nasdaq, I will sell enough from my taxable account to wipe out the balance.
I don't believe LymPro is a dud. I think it will be a fine product but will take time to gain traction in the research market. I think Gerald saw an opportunity to corner the AD diagnostic blood test market and took the actions he did to add to the benefit LymPro offers, not because it didn't pan out. I can see that once we bring the full spectrum of blood analysis assets to market, not only will new AD drugs be using multiple tests to screen patients, but many drugs previously failed will be retested under this broad blood-based test series. I believe it quite possible that AD may already have an effective treatment that previously failed due to ineffective screening methods.
I've taken a lot greater risk than most investors in this company. I'm not blind to the risk we continue to face. But one thing I won't do is trash the company because I am unhappy with my investment results to date. I'm not dissatisfied, but I also have an average price of 0.043. I know a lot of folks here are much higher than that, so that affects their frustration level.
If I ever change my outlook on the company's future, I'll quietly sell my shares and move on. I'll make a single post announcing my actions after it's done, and I'll wish everyone the best, but I won't post after I've exited the investment. I'm certainly not going to trash the company publicly while I'm trying to reduce or eliminate my holdings. Only a moron would do that, but that's just my opinion.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼